Sanofi $SNY Shares Acquired by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 90.7% during the third quarter, Holdings Channel.com reports. The fund owned 29,940 shares of the company’s stock after acquiring an additional 14,237 shares during the period. MidWestOne Financial Group Inc.’s holdings in Sanofi were worth $1,413,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of SNY. Financial Consulate Inc. purchased a new stake in Sanofi during the 3rd quarter worth approximately $26,000. First Horizon Corp acquired a new stake in shares of Sanofi during the third quarter worth $33,000. Salomon & Ludwin LLC grew its holdings in shares of Sanofi by 1,046.3% during the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after buying an additional 701 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Sanofi by 233.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after acquiring an additional 700 shares during the period. Finally, Traub Capital Management LLC purchased a new position in Sanofi in the 2nd quarter worth $51,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $46.01 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.29. The stock has a market capitalization of $112.22 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 1.22 and a beta of 0.45. The firm’s 50 day simple moving average is $47.73 and its 200-day simple moving average is $48.60. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.

Analyst Ratings Changes

SNY has been the topic of several research analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Citigroup assumed coverage on shares of Sanofi in a research report on Tuesday, January 27th. They set a “neutral” rating for the company. HSBC reaffirmed a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Finally, Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Hold” and a consensus target price of $62.67.

Key Stories Impacting Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.